Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
pharmaceutical drug
|
| gptkbp:activeDuring |
calcifediol
|
| gptkbp:availability |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:clinicalTrials |
Phase 3
NCT02415545 NCT02415558 managing vitamin D deficiency |
| gptkbp:contraindication |
dizziness
headache allergic reactions dry mouth skin rash severe renal impairment hypercalcemia vitamin D toxicity |
| gptkbp:date |
2016-12-23
|
| gptkbp:dosageForm |
softgel capsule
|
| gptkbp:drugInterdiction |
Yes
absorbed in the gastrointestinal tract anticonvulsants thiazide diuretics digoxin vitamin D analog |
| gptkbp:education |
patient counseling required
|
| gptkbp:endOfLife |
approximately 3 weeks
|
| gptkbp:formulation |
capsule
|
| gptkbp:hasPopulation |
adults with CKD
|
| gptkbp:healthcare |
important for efficacy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rayaldee
|
| gptkbp:is_monitored_by |
renal function
serum calcium levels serum phosphate levels |
| gptkbp:label |
gptkb:Bristol-Myers_Squibb_Company
|
| gptkbp:mandates |
chronic kidney disease stage 3 or 4
|
| gptkbp:manufacturer |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:marketSegment |
available
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:offers |
varies by pharmacy
|
| gptkbp:packaging |
blister pack
|
| gptkbp:patentStatus |
patented
|
| gptkbp:patentType |
Yes
|
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
fatigue
nausea vomiting constipation hypercalcemia |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
increases serum levels of calcitriol
|
| gptkbp:usedFor |
treatment of secondary hyperparathyroidism
|
| gptkbp:waterManagement |
urine
|